Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Arbutus Biopharma

Arbutus Biopharma (NASDAQ: ABUS) insider transactions

In the twelve months to 10 November 2026, executives and directors of Arbutus Biopharma reported no open-market sales and no open-market purchases, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Arbutus Biopharma shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
1 October 2026Androski LindsayPresident and CEOReturned to the company−24,655$5.0047,682Form 4
1 October 2026Sawhney RogerDirectorReturned to the company−17,142$5.0013,683Form 4
1 October 2026Nguyen TuanChief Financial OfficerReturned to the company−48,081$5.00111,882Form 4
1 October 2026Beardsley Robert ADirectorReturned to the company−17,948$5.0014,328Form 4
18 September 2026Beardsley Robert ADirectorOption exercise+52,533$3.2052,533Form 4
18 September 2026Beardsley Robert ADirectorOption exercise+78,800$4.24131,333Form 4
18 September 2026Beardsley Robert ADirectorShares withheld for tax−99,057$5.0732,276Form 4
18 September 2026Sawhney RogerDirectorOption exercise+52,533$3.3452,533Form 4
18 September 2026Sawhney RogerDirectorOption exercise+78,800$4.24131,333Form 4
18 September 2026Sawhney RogerDirectorShares withheld for tax−100,508$5.0730,825Form 4
18 September 2026Nguyen TuanChief Financial OfficerOption exercise+265,625$3.49339,125Form 4
18 September 2026Nguyen TuanChief Financial OfficerOption exercise+27,475$4.39366,600Form 4
18 September 2026Nguyen TuanChief Financial OfficerShares withheld for tax−206,637$5.07159,963Form 4
18 September 2026Androski LindsayPresident and CEOOption exercise+116,408$3.20144,408Form 4
18 September 2026Androski LindsayPresident and CEOOption exercise+10,456$4.39154,864Form 4
18 September 2026Androski LindsayPresident and CEOShares withheld for tax−82,527$5.0772,337Form 4
2 February 2026Androski LindsayPresident and CEOGrant or award+28,000—28,000Form 4
2 February 2026Nguyen TuanChief Financial OfficerGrant or award+73,500—73,500Form 4
14 February 2025Sims KarenChief Medical OfficerGrant or award+49,300—155,494Form 4
14 February 2025Hastings David CChief Financial OfficerGrant or award+90,100—249,824Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Arbutus Biopharma page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.